Hematopoietic Cell Transplantation for Testicular Cancer (CPB 0617, reviewed 2026-09-03)
Summary
Aetna's Clinical Policy Bulletin 0617 covers hematopoietic cell transplantation for testicular cancer. Autologous transplant is medically necessary when criteria are met for patients who do not reach complete remission after an initial course of standard-dose chemotherapy (refractory disease or a partial response), as consolidation therapy after relapse following that course, or as tandem autologous transplant for relapsed disease. Autologous transplant as initial treatment in place of standard-dose chemotherapy with FDA-approved drugs, and allogeneic transplant for testicular cancer, are considered experimental, investigational or unproven.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.